Turning Setbacks into Success: Translational Science in Action
🎙️Join us for an insightful session with guest speaker John Dulos, a renowned translational science expert and co-inventor of anti-PD1 pembrolizumab (Keytruda). This webinar will explore the pivotal role of translational science and how lab findings transform into life-saving treatments.
đź‘Ą Hosted by: Venn Life Sciences
🔑Key Learnings:
• Developing a clear translational plan early on
• How clinical failures can lead to unexpected new opportunities
• Leveraging multidisciplinary teams for smarter drug development
• De-risking through patient stratification & biomarker strategies
About the Speaker:
​​​​​​​
With a PhD in Immunology from Utrecht University, John has 30+ years of experience in the pharmaceutical and biotech industry.
John has ample expertise and proven track record in research and development and translational science in the industry setting (Organon, Schering Plough, MSD/Merck, Crucell/Johnson & Johnson, TNO Triskelion, Aduro/Chinook and Galapagos) in various disease areas, e.g. cancer (-immunotherapy), autoimmune-, infectious- and muscular and fibrotic kidney diseases.
•Co-inventor and translational lead of anti-PD1 pembrolizumab (Keytruda, MSD/Merck) and awarded inventor of the year in cancer immunotherapy by the Intellectual Property Owners Education Foundation in 2016
•Co-inventor and project/translational lead of anti-APRIL (BION-1301) for the subcutaneous treatment of IgA Nephropathy which is currently in phase 3 clinical trials at Novartis
•Co-inventor and translational lead of GLPG1972 for the treatment of Duchenne Muscular- and Kidney-diseases
•Currently translational lead for small molecules, biologics antibodies and ATMPs in immunology and oncology at Galapagos
🎟️ Replay: FREE of charge
Gain practical insights from real-world case studies on adapting and advancing in the field.
Don’t miss this opportunity to turn setbacks into success!
​​​​​​​
You can view this webinar from your computer, tablet or mobile phone.
đź‘Ą Hosted by: Venn Life Sciences
🔑Key Learnings:
• Developing a clear translational plan early on
• How clinical failures can lead to unexpected new opportunities
• Leveraging multidisciplinary teams for smarter drug development
• De-risking through patient stratification & biomarker strategies
About the Speaker:
​​​​​​​
With a PhD in Immunology from Utrecht University, John has 30+ years of experience in the pharmaceutical and biotech industry.
John has ample expertise and proven track record in research and development and translational science in the industry setting (Organon, Schering Plough, MSD/Merck, Crucell/Johnson & Johnson, TNO Triskelion, Aduro/Chinook and Galapagos) in various disease areas, e.g. cancer (-immunotherapy), autoimmune-, infectious- and muscular and fibrotic kidney diseases.
•Co-inventor and translational lead of anti-PD1 pembrolizumab (Keytruda, MSD/Merck) and awarded inventor of the year in cancer immunotherapy by the Intellectual Property Owners Education Foundation in 2016
•Co-inventor and project/translational lead of anti-APRIL (BION-1301) for the subcutaneous treatment of IgA Nephropathy which is currently in phase 3 clinical trials at Novartis
•Co-inventor and translational lead of GLPG1972 for the treatment of Duchenne Muscular- and Kidney-diseases
•Currently translational lead for small molecules, biologics antibodies and ATMPs in immunology and oncology at Galapagos
🎟️ Replay: FREE of charge
Gain practical insights from real-world case studies on adapting and advancing in the field.
Don’t miss this opportunity to turn setbacks into success!
​​​​​​​
You can view this webinar from your computer, tablet or mobile phone.
